This document is a patent grant notice for US Patent No. 12595232B2, covering a novel MDM2 inhibitor compound invented by researchers at Bahcesehir University. The patent, classified under CPC codes including C07D 209/18 and A61P 35/02 (anticancer), protects the use of formula (I) compounds as MDM2 inhibitors.

Pharmaceutical companies and researchers developing oncology drugs targeting the MDM2 pathway should review this patent to understand existing IP coverage. Parties conducting research in this area may need to seek licensing or design around the patented compounds to avoid infringement.